Commercial-stage biopharmaceutical company InnoCare Pharma (HKEX:09969) (SSE:688428) and biotechnology company Keymed Biosciences Inc (HKEX:02162) announced on Monday that they have entered into an exclusive licence agreement with Prolium Bioscience for the development and commercialisation of ICP-B02, a CD20xCD3 bispecific antibody.
Under the terms of the deal Prolium, a Delaware company funded and backed by New York-based investment firm RTW Investments LP, will have the exclusive right to develop and commercialise ICP-B02 globally in non-oncology and in ex-Asia regions for oncology.
InnoCare and KeyMed will receive up to USD520m in milestone payments and royalties on future net sales, as well as a minority equity stake in Prolium.
ICP-B02 is a CD20xCD3 bispecific antibody jointly developed by InnoCare and KeyMed. A Phase I/II clinical trial in China is ongoing to evaluate its safety and efficacy in relapsed/refractory Non-Hodgkin lymphoma.
Biophytis signs co-development agreement with AskHelpU for ALS in China
Nanobiotix reports first patient dosed in Phase 2 lung cancer study
Takeda's FRUZAQLA receives Health Canada market authorisation for metastatic colorectal cancer
InnoCare and KeyMed license CD20xCD3 bispecific antibody to Prolium
GSK's Jemperli receives expanded EU approval for endometrial cancer treatment
AstraZeneca's Datroway approved in US for HR-positive breast cancer
Amgen's LUMAKRAS (sotorasib) in combination with Vectibix (panitumumab receives US FDA approval
Guangzhou Fermion Technology partners with Simcere Pharmaceutical
Zai Lab submits New Drug Application for KarXT to treat schizophrenia in China
Telix Pharmaceuticals' Illuccix gets European approval
Innovent and ASK Pharm's limertinib NDA receives Chinese regulatory approval
RYBREVANT approved in Canada for second-line EGFR-mutated lung cancer
Charles River and Akron Bio collaborate to enhance cell therapy manufacturing
Avacta Group reports positive data from AVA6000 Phase 1 trial in salivary gland cancer